-
NMPA Reclassifies Omeprazole Tablets from Prescription to OTC Status
•
The National Medical Products Administration (NMPA) announced that omeprazole enteric-coated tablets have been reclassified from prescription-only to over-the-counter (OTC) status in China. The 10mg dosage is approved for short-term relief of heartburn and acid reflux symptoms caused by hyperacidity. Regulatory UpdateMarketing Authorization Holders (MAHs) are required to submit revised package…
-
Henlius Biotech’s PD-1 Inhibitor Serplulimab Secures NMPA Review for Esophageal Cancer
•
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has accepted a supplementary Biologic License Application (BLA) for its PD-1 inhibitor Serplulimab (HaiSiZhuang) in combination with cisplatin and fluorouracil (5-FU) for first-line treatment of locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). Additionally,…
-
Acchrom Tech Raises USD 14.45M in Angel Round Led by BioTrack Capital to Expand Chromatography Solutions
•
Beijing-based chromatography specialist Acchrom Tech has raised RMB 100 million (USD 14.45 million) in an angel financing round led by BioTrack Capital, with contributions from CDBI Partners and SDIC Unity Capital. The funds will be used to enhance complete chromatography solutions and expand sales channels. Company ProfileFounded in 2015, Acchrom…
-
JD Healthcare’s H1 2022 Financial Report Shows Strong Growth in Revenue and Profits
•
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), reported robust financial results for H1 2022, with total revenues reaching RMB 20.2 billion (USD 2.94 billion), up 48.3% year-on-year (YOY). Non-IFRS net profits surged 82.0% YOY to RMB 1.21 billion (USD 176.6 million). As of June 30, 2022,…
-
Everest Medicines CEO Resigns as Trodelvy Sale Completed
•
China-based biotech Everest Medicines (HKG: 1952) announced the resignation of CEO Dr. Kerry Blanchard, effective immediately. Blanchard will remain as an advisor for six months, while the company stated a replacement has been selected and will be named within the next month. Leadership TransitionThe company did not specify a reason…
-
Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech
•
Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B financing round led by Oriental Fortune Capital, with contributions from Haitong Innovation Private Fund, Sun Rock Capital, Center Lab, and YuanChuang Capital. The proceeds will fund commercialization of core drug candidates and pivotal clinical studies…
-
Lab Direct Raises USD 10M in Series A+ to Expand Digital Supply Chain Platform
•
Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in a Series A+ financing round led by Bayland Capital, a joint biomedical fund established by Contract Research Organization (CRO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) and Legend Capital. The round included participation from…
-
Health Plus Receives Strategic Investment from Meinian Onehealth to Drive Healthcare Innovation
•
Beijing-based Health Plus, a third-party digital managed healthcare service platform, has received strategic investment from Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044), also known as Health-100. The partnership will see both companies collaborate on commercial insurance product innovation, medical network construction, and healthcare service integration. Collaboration DetailsThe two firms…
